Eisai
Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan
Phil Taylor
Aduhelm, Alzheimer's disease, Biogen, Eisai, fda, lecanemab, neurology, regulatory
0 Comment
Eisai’s brain health tool NouKNOW used in Tokyo dementia project
Phil Taylor
app, dementia, digital, digital health, Eisai, smartphones
0 Comment
ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC
Phil Taylor
antibody-drug conjugate, Bristol-Myers Squibb, Eisai, immunogen, Oncology, ovarian cancer
0 Comment
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
Phil Taylor
Aduhelm, Alzheimer's disease, amyloid, Biogen, Eisai, lecanemab, regulatory
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Idorsia is first to EU market with orexin insomnia drug
Phil Taylor
Belsomra, Dayvigo, Eisai, EU, Idorsia, insomnia, Quviviq, regulatory approval
0 Comment
Pharma group seeks digital measure standards for Alzheimer’s
Phil Taylor
Alzheimer's disease, Biogen, digital, digital health, Digital Medicine Society (DiMe), Eisai, Eli Lilly, Merck & Co
0 Comment
News/ News/ Sales and Marketing
Eisai hands off responsibility for Aduhelm to Biogen
Phil Taylor
Aduhelm, Alzheimer's disease, Biogen, Eisai, Financial, neurology
0 Comment
Roche starts new four-year trial of Alzheimer’s drug gantenerumab
Phil Taylor
Alzheimer's disease, Biogen, donanemab, Eisai, Eli Lilly, gantenerumab, lecanemab, neurology, Roche
0 Comment